Randlab Group

What Randlab Group does

Randlab Group is an Australian-headquartered veterinary pharmaceutical company founded in 2004 that develops, manufactures, and distributes proprietary equine medicines and nutritional supplements globally. The company's product portfolio is organized into nine therapeutic suites — Gastric Ulcer, Joint, Reproduction, Anti-inflammatory, Sedatives & Anaesthesia, Respiratory, Antimicrobial, Wormer, and Nutritional Supplements — covering approximately 50+ stock-keeping units across oral pastes, injectables, oral gels, suspensions, ointments, and oral powders. Core technical capabilities centre on enteric-coated and buffered omeprazole formulations (Ulcershield, Gastropell Forte, Gastropell Daily, GoldGuard) for treatment and prevention of gastric ulcers, polysulfated glycosaminoglycan (PSGAG) and pentosan polysulfate injections for degenerative joint disease, sodium hyaluronate intravenous formulations for non-infectious synovitis, and a full suite of NSAIDs (meloxicam, phenylbutazone, flunixin), reproductive hormones (deslorelin, altrenogest), sedatives (detomidine, xylazine, acepromazine), and parasiticides (ivermectin, moxidectin, praziquantel combinations).

Randlab operates a sales-led go-to-market model that routes products primarily through veterinary medicines wholesalers to registered equine veterinarians, supplemented by direct office sales in seven countries (Australia, Belgium, China, Dubai, New Zealand, Singapore, USA). The company does not publish consumer pricing and bills on a per-unit wholesale basis; revenue is generated entirely through one-time unit sales of medicines and supplements rather than subscriptions or licensing. Primary customer segments are equine veterinarians (the prescribing channel) and horse owners (downstream purchasers), with secondary focus on performance horses — racehorses, show horses, endurance, and competition horses — where gastric ulcer prevalence reaches 95% in thoroughbreds and standardbreds in training.

In early 2025, Randlab was acquired by Animalcare Group, a York-headquartered animal health company listed on the London Stock Exchange, and was identified as a key driver of Animalcare's FY2025 performance (20% revenue growth to £89.1m and 52.6% underlying EBITDA growth to £17.7m). Animalcare itself subsequently became the subject of a £235.2m take-private transaction by Charterhouse Capital Partners in 2026. Randlab currently operates as a specialty subsidiary within the Animalcare portfolio, retaining its seven-country office network, its wholesale distribution relationships, and an internal Global Technical Veterinarian (Dr Michael Robinson, BVSc PhD) who oversees pharmacovigilance and technical support.

Name

Randlab Group

Legal name

Randlab Pty Ltd

Website

https://randlab.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Randlab Group is an Australian equine veterinary pharmaceutical company that develops and distributes proprietary medicines and supplements for horses across nine therapeutic suites, selling through veterinary wholesalers in seven countries.

Ownership category

akta.pro rank

Product category

Equine Veterinary Pharmaceuticals

NAICS

Veterinary Services (54194), Animal Food Manufacturing (3111), Animal Food Manufacturing (31111)

SIC

Pharmaceutical Preparations (2834), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Equine Therapeutics (Rx) (HLAMAEAC)

akta.pro secondary industries

Equine Nutrition & Therapeutic Diets (HLAMAHAE), Equine Supplements & Additives (Vitamins/Minerals, Joint, Digestive, Electrolytes) (AFADAEAG), Equine Medicated & Functional Feeds (Gastrointestinal Support, Calming, Hoof/Coat Functional Claims) (AFADAEAJ), Equine Veterinary Services (AFAEANAC)

Keywords

• Equine veterinary medicines
• Veterinary pharmaceuticals
• Animal health supplements
• Gastric ulcer treatments
• Equine joint therapy

Headquarters

HQ city

Chipping Norton

HQ country

Australia

HQ region

Oceania

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Veterinary Medicines Sales: Randlab generates revenue through the sale of proprietary veterinary medicines and supplements for equine veterinarians and horse owners. The company was acquired by Animalcare Group in early 2025 and contributes to its parent company's revenue of £89.1m for FY2025.
2. Equine Supplements: Sale of oral and injectable nutritional supplements for horses including joint support, electrolytes, vitamins, and performance supplements.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Randlab Group develops, manufactures, and distributes a comprehensive portfolio of proprietary equine veterinary medicines and nutritional supplements for equine veterinarians and horse owners worldwide. The product range spans gastric ulcer treatments, joint disease therapies, reproductive cycle management, anti-inflammatory and analgesic products, sedatives and anaesthesia, respiratory treatments, antimicrobials, wormers, and nutritional supplements, distributed through veterinary wholesalers across seven country offices.

Product overview

Randlab Group is a veterinary pharmaceutical company established in 2004 that provides premium, innovative and cost-effective veterinary medicines and supplements for equine veterinarians and horse owners. The company operates as a single unified product portfolio rather than a platform-plus-modules architecture. The product range is organized into therapeutic suites: Gastric Ulcer Suite (Ulcershield, Gastropell Forte, Gastropell Daily, GoldGuard - all omeprazole-based treatments), Joint Suite (Zycan, Arthropen Vet 250, Arthropen Vet, Matrix 6000, Equinate I.A./I.V., Equinate I.V., Intra-Log, Gold-Cort - injectable joint and anti-inflammatory treatments), Reproduction Suite (Biorelin, Ovu-Mate Injection, Ovu-Mate Oral Solution - reproductive cycle management), Anti-inflammatory Suite (Colix, Meloxicam products, Platinum Bute, Equine Bute Paste, Dex), Sedatives & Anaesthesia Suite (Butorphanol, Ketamine, Sedator, Xylazine, Sed-Ace), Respiratory Suite (Airway Tmps, Airway Gel, Bromo Tmps), Antimicrobial Suite (TMPS Paste, Metronidazole, Vetedine, Gentamicin, Tri-Sulfox, Tri-Sil), Wormer Suite (Goldmectin, Oxfendoate, ProMax, Pradectin), and Nutritional Supplements (BC5aa, Alljoints, Supervites, Electrolene, Kentucky Gold, Hoof Gold, Optimise X, Phosforte B). The company also offers euthanasia and diuretic products. Randlab has global offices in Australia, Belgium, China, Dubai, New Zealand, Singapore, and USA, and was acquired by Animalcare Group in January 2025.

Differentiator

Problem solved

Functional benefit

Products and services

• Ulcershield Oral Paste Omeprazole 370 mg/g buffered paste for treatment and prevention of gastric ulcers in horses. Features pH-stable buffered paste technology (patent pending) to protect the active ingredient.
• Gastropell Forte Oral Paste Double-strength enteric-coated Omeprazole oral paste for treatment and prevention of gastric ulcers in horses, particularly in high performance horses and chronic, recurrent or severe cases (patent pending).
• Gastropell Daily Oral Paste Enteric-coated Omeprazole oral paste for treatment and prevention of low-grade gastric ulceration, designed for horses in light work or under low-stress scenarios, including foals and ponies.
• GoldGuard Oral Paste Omeprazole 370 mg/g pH-stable paste for treatment and prevention of gastric ulcers in horses.
• Zycan Injection Disease Modifying Osteoarthritis Drug (DMOAD) containing Polysulfated Glycosaminoglycan 100 mg/mL for treatment of degenerative and traumatic aseptic joint disease in horses.
• Arthropen Vet 250 Injection High-concentration Pentosan Polysulfate Sodium 250 mg/mL injection designed for low-volume administration in horses with non-infectious inflammatory joint disease.
• Matrix 6000 I.V. Injection High molecular weight, high viscosity microbial-source sodium hyaluronate 10 mg/mL for intravenous treatment of lameness associated with non-infectious synovitis and degenerative joint disease in horses.
• Equinate I.A./I.V. Injection Sodium Hyaluronate injection designed for intra-articular administration and may also be used intravenously for treatment of lameness associated with non-infectious synovitis and degenerative joint disease in horses.
• Intra-Log Injection Triamcinolone Acetonide 6 mg/mL potent synthetic corticosteroid for treatment of inflammation, allergic disorders, dermatologic disorders, and arthritis in dogs, cats, and horses.
• Ovu-Mate Altrenogest Injection for Horses Altrenogest 50 mg/mL injection for regulation and control of breeding cycle in mares, suppressing oestrus cycle and preventing signs of heat and ovulation.
• Biorelin Deslorelin 1.25mg/mL Injection GnRH analogue injection containing Deslorelin 1.25 mg/mL for induction of ovulation within 48 hours in oestrous mares with ovarian follicle greater than 30 mm diameter.
• Colix Injection NSAID containing Flunixin Meglumine equivalent to Flunixin 50 mg/mL for alleviation of inflammation and pain in horses, cattle, pigs, and dogs, and treatment of endotoxic shock.
• Randlab Meloxicam Injection Non-steroidal anti-inflammatory analgesic-antipyretic containing Meloxicam 20 mg/mL for horses, cattle, pigs, and sheep, with preferential COX-2 inhibitory properties.
• Sedator Injection Detomidine Hydrochloride 10 mg/mL dose-controlled sedative and analgesic for mild to heavy sedation, examinations, minor surgical procedures, and control of pain in uncomplicated colic in horses.
• Randlab Xylazine 100 Injection Xylazine as hydrochloride 100 mg/mL sedative, analgesic, and skeletal muscle relaxant injection for horses with rapid onset of action.
• Airway Tmps Oral Powder Oral bronchodilator and antibacterial containing Clenbuterol Hydrochloride, Sulfadiazine, and Trimethoprim for treatment of respiratory diseases in horses.
• Vetedine Ointment Povidone-Iodine 100 mg/g ointment with potent prolonged antibacterial, antifungal, and virucidal activity for topical disinfection and antisepsis in horses, cattle, swine, sheep, and dogs.
• Goldmectin LV Ivermectin Oral Paste for Horses Ivermectin 18.7 mg/g and Praziquantel 140 mg/g oral paste for treatment and control of susceptible tapeworms, roundworms, bots, and skin lesions caused by Habronema, Draschia, and Onchocerca spp. in horses.
• Pradectin with Tape Gel Wormer Long-acting wormer containing Moxidectin 20 mg/mL and Praziquantel 125 mg/mL with extended Egg Reappearance Period of at least 14 weeks for comprehensive parasite control in horses.
• Alljoints Joint cartilage repair and maintenance supplement containing Collagen Hydrolysate, Chondroitin Sulphate, Glucosamine Sulphate, Green Lipped Mussel Powder, and Vitamin E per 20 g dose.
• Supervites Premium electrolytes, vitamins, and antioxidants supplement containing sodium, potassium, calcium, magnesium, and B-complex vitamins for rehydration and recovery after sweat loss and strenuous exercise in horses.
• Electrolene Paste Oral electrolyte paste containing B Group Vitamins, Vitamin E, and Folic Acid with essential electrolytes and zinc for hard working or dehydrated horses.
• Hoof Gold Nutritional supplement for inclusion in horse feed containing a combination of nutrients for health of hooves, hair, and skin, in 1.5 kg packaging.
• Randlab Frusemide Injection Furosemide 50 mg/mL diuretic and saluretic injection for dogs, cats, horses, and cattle.
• Lethaton Euthanasia Solution Pentobarbitone sodium 300 mg/mL euthanasia solution for use only by registered veterinarians; not to be used as anesthetic.

Quantifiable outcome

• 95% of thoroughbred and standardbred racehorses in training have gastric ulcers, making Randlab's ulcer treatments essential for the performance horse market
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• Animalcare GroupcoreStrategic or Co-development PartnerRandlab was acquired by Animalcare Group at the start of 2025. Animalcare is a York-headquartered animal health company listed on the London Stock Exchange. Randlab's contribution was a key driver of Animalcare's 20% revenue growth to £89.1m and 52.6% EBITDA increase to £17.7m in FY2025.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Ceva Santé Animale: Global animal health company with equine product lines across reproduction, pain management, and anti-infectives — competing with Randlab's Reproduction, Anti-inflammatory, and Antimicrobial Suites across Europe and emerging markets.
• Zoetis: World's largest animal health company with a broad equine portfolio including GastroGard (omeprazole) and joint therapies (Hyvisc/Polyglycan), directly competing with Randlab's ulcer and joint suites across global markets.
• Virbac: Independent global animal health company with an equine portfolio spanning parasiticides, anti-inflammatories, and reproduction products, directly comparable to Randlab's Wormer, Anti-inflammatory, and Reproduction Suites.
• Boehringer Ingelheim Animal Health: Major animal health player offering equine pharmaceuticals across joint, respiratory, and parasite control categories — overlapping significantly with Randlab's product suites and competing for the same equine veterinarian customers.
• Elanco Animal Health: Large diversified animal health company with equine products across anti-infectives, parasiticides, and joint health, competing with Randlab's antimicrobial, wormer, and joint suites in the global equine channel.

Direct peers

• Vetoquinol: Independent veterinary pharmaceutical company focused on equine and companion animal products, with overlapping anti-inflammatory, joint, and reproductive offerings and similar global wholesaler-led distribution model.
• Norbrook Laboratories: Privately held veterinary pharmaceutical manufacturer offering NSAIDs (e.g., phenylbutazone, meloxicam), antimicrobials, and parasiticides — directly competing with Randlab's anti-inflammatory, antimicrobial, and wormer portfolios.
• Dechra Pharmaceuticals: Specialty veterinary pharmaceutical company (acquired by EQT) with strong positions in equine endocrinology, reproduction, and pain management — directly overlapping Randlab's Reproduction Suite (Biorelin/Ovu-Mate) and anti-inflammatory portfolio.

Emerging players

• Kyron Labs: South Africa-based veterinary pharmaceutical manufacturer focused on equine and production animal therapeutics, with overlapping omeprazole, anti-inflammatory, and supplement offerings to Randlab's product range.

Regional players

• BOVA Australia: Australian specialty veterinary compounding and pharmaceutical supplier focused on equine and companion animal products, competing with Randlab in the home Australian market across supplements and specialty therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/randlab
• LinkedInlinkedin.com/company/randlab-pty-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Randlab Group